References
Diekema D, Jones R. Oxazolidinones: a review. Drugs 2000; 59(1): 7–16
Clemett D, Markham A. Linezolid. Drugs 2000; 59(4): 815–27
Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001; (61) 4: 525–551
Pharmacia and Upjohn Company. Kalamazoo, USA. Linezolid prescribing information. Available from: URL: http://www.zyvox.com/fullprescribe.htm [Accessed 2001 Apr 12]
Wise R. Linezolid: a viewpoint by Richard Wise. Drugs 2000; 59(4): 828
Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–45
Schaadt RD, Batts DH, Daley-Yates PT, et al. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Diagn Microbiol Infect Dis 1997; 28: 201–4
Cammarata SK, Hafkin B, Demke DM, et al. Efficacy of linezolid in skin and soft tissue infections [abstract]. Clin Microbiol Infect 1999; 5 Suppl. 3: 133
Cammarata SK, Hafkin B, Todd WM, et al. Efficacy of linezolid in community-acquired S. pneumoniae pneumonia [abstract]. Am J Respir Crit Care Med 1999; 159 Suppl. Pt 2 (3): A844
Anon. First resistance to linezolid reported. Scrip Mag 1999 Oct 6; 2478: 23
Lobeck F, Anderson DC, Bruss JB, et al. Linezolid for the treatment of pneumonia in hospitalized children: an open-label, single-arm, multicenter study [abstract]. 9th International Congress on Infectious Diseases; Apr 10–13: Buenos Aires, 117
Birmingham MC, Zimmer GS, Hafkin B, et al. Outcomes with linezolid from an ongoing compassionate use (CU) trial of patients (pts) with significant, resistant Gram-positive infections [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Nov 18–24; Buffalo, NY: 724
Birmingham MC, Zimmer GS, Flavin SM, et al. Results of treating bacteraemic patients with linezolid in a compassionate use trial for resistant, gram-positive infections [abstract]. Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America; 1999 Nov 18–21; Philadelphia, PA: 129
Duvall SE, Sseas C, Bruss JB, et al. Comparison of oral linezolid to oral Clarithromycin in the treatment of uncomplicated skin infections: results from a multinational phase III trial [abstract]. 9th International Congress on Infectious Diseases; 2000 Apr 10–13: Buenos Aires, 181
Cammarata SK, Schueman LK, Timm JA, et al. Oral linezolid in the treatment of community-acquired pneumonia: a phase III trial [poster no. E-73]. American Thoracic Society; 2000 May 5: Toronto
Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44(12): 3408–13
Cammarata SK, San Pedro GS, Timm JA, et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia [poster no. 237]. American Thoracic Society 2000 May 5, Toronto
Cammarata SK, Hempsall KA, Timm JA, et al. Linezolid is superior to Cephalosporins in treatment of patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia [abstract]. Am J Resp Crit Care Med 2000; 161 Pt 2 suppl. A654
Leach TS, Kaja RW, Eckert SM, et al. Linezolid versus vancomycin for the treatment of MRS A infections: results of a randomized phase III trial [abstract]. 9th International Congress on Infectious Diseases; 2000; Apr 10–13: Buenos Aires, 224
Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2000; 32: 402–12
Hartman CS, Leach TS, Kaja RW, et al. Linezolid in the treatment of vancomycin-resistant enterococcus: a dose comparative, multicenter phase III trial [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20: Toronto, 488
Fines M, Leclercq R. Influence of mechanisms of resistance to antiobiotics that bind to the 50S ribosomal subunit on the activity of linezolid against gram-positive organisms. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, CA: C183
Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with Linezolid [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 24–2; San Francisco, CA: 118
Wilks NE, McConnell-Martin MA, Oliphant TH. Safety and tolerance of linezolid in phase II trials [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 24–27; San Francisco, CA: 40
Noskin GA. Linezolid: a viewpoint by Gary A. Noskin. Drugs 2000; 59(4): 828
Rittenhouse BE, Li Z, Willke RJ, et al. Re-examining hospital length of stay (LOS) reduction potential in a randomized, multi-center clinical trial of methicillin-resistant Staphylococcal species (MRSS): linezolid vs. vancomycin [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20: Toronto, 510
Li ZJ, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21(3): 263–274
Rights and permissions
About this article
Cite this article
Linzolid: first of a new drug class for Gram-positive infections. Drugs Ther. Perspect 17, 1–6 (2001). https://doi.org/10.2165/00042310-200117090-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200117090-00001